Skip to main content

Table 1 Demographic and tumour characteristics of women undergoing neoadjuvant chemotherapy according to drug regimen

From: The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET

Characteristic

TAX → FEC

FEC → TAX

P valuea

Age

52 (37-70)

48 (30-66)

0.04b

Pathology type

   

   Ductal

25/31 (80.6)

25/29 (86.2)

1.00

   Ductal/lobular

2/31 (6.5)

1/29 (3.4)

n/a

   Lobular

4/31 (13.4)

3/29 (10.3)

n/a

Pathology grade

   

   Low

4/31 (12.9)

2/29 (6.9)

0.41

   Medium

11/31 (35.5)

10/29 (34.5)

0.82

   High

16/31 (51.6)

17/29 (58.6)

0.86

Oestrogen receptor status

   

   Negative

10/31 (32.2)

13/29 (44.8)

0.29

   Positive

21/31 (67.7)

16/29 (55.2)

0.25

Progesterone receptor status

   

   Negative

16/31 (51.6)

18/29 (62.1)

0.60

   Positive

15/31 (48.4)

11/29 (37.9)

0.33

HER2 statusc

   

   Negative

17/29 (58.6)

16/29 (55.2)

1.00

   Positive

12/29 (41.4)

13/29 (44.8)

1.00

Surgical procedured

   

   Mastectomy

16/30 (53.3)

17/29 (58.6)

0.86

   Wide local excision

13/30 (43.3)

12/29 (41.3)

0.84

   Partial mastectomy

1/30 (3.3)

0/29 (0.0)

n/a

  1. Demographic and tumour characteristics of women undergoing neoadjuvant chemotherapy for locally advanced breast cancer according to drug regimen (n = 34/group). TAX, docetaxel (Taxotere®); FEC, combined flourouracil-epirubicin-cyclophosphamide anthracycline-based chemotherapy; n/a, not available. Data presented as median (range) or n/N (%). aChi-square test. bMann-Whitney U test. cNot available for two patients in Arm 1 (TAX → FEC). dOne woman in Arm 1 declined surgery.